Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
  • Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Patterns of recurrence after prostate bed radiotherapy.

Thumbnail
View/Open
Accepted version (533.3Kb)
Date
2019-12
ICR Author
Murray, Julia
Dearnaley, David
Brand, Douglas
Eeles, Rosalind
Huddart, Robert
Parker, Chris
van As, Nick
Tree, Alison
Show allShow less
Author
Brand, DH
Parker, JI
Dearnaley, DP
Eeles, R
Huddart, R
Khoo, V
Murray, J
Suh, Y-E
Tree, AC
van As, N
Parker, C
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Background and purpose Prostate bed radiotherapy is a standard treatment after radical prostatectomy. Recent evidence suggests that, for patients with a PSA > 0.34 ng/ml, the radiotherapy treatment volume should include not only the prostate bed but also the pelvic lymph nodes. We describe the patterns of failure after prostate bed radiotherapy, focussing on the proportion of patients with radiologically confirmed pelvic nodal failure only, in the absence of distant disease.Materials and methods Patients included were men receiving prostate bed radiotherapy at the Royal Marsden Hospital between 1997 and 2013. The key outcome of interest was the pattern of radiologic failure after prostate bed radiotherapy. Baseline characteristics of patients experiencing pelvic nodal failure without distant disease were compared versus all other relapse patterns. Comparisons were by Chi-square test, with multiple testing adjusted p < 0.005 significant.Results 140 of 322 patients developed biochemical failure after salvage RT. Radiologic failure occurred in 89 patients. 35 of the 89 patients (39%) with radiologic failure had pelvic nodal failure without distant disease, with no significant differences in baseline characteristics when compared to all other patients. The rate of pelvic nodal failure was the same for patients with PSA above or below 0.34 ng/ml (16/149, 95% CI = 6-17% vs 19/171, 95% CI = 7-17%).Conclusions Pelvic lymph node disease, without more distant disease, is a common site of failure in men receiving radiotherapy to the prostate bed, including those with PSA < 0.34 ng/ml. This observation informs the case for including the pelvic lymph nodes in the radiotherapy treatment volume.
URI
https://repository.icr.ac.uk/handle/internal/3382
DOI
https://doi.org/10.1016/j.radonc.2019.09.007
Collections
  • Closed Research Teams
  • Genetics and Epidemiology
  • Radiotherapy and Imaging
Subject
Pelvis
Lymph Nodes
Humans
Prostatic Neoplasms
Neoplasm Recurrence, Local
Prostate-Specific Antigen
Adult
Aged
Middle Aged
Male
Research team
Clinical Academic Radiotherapy (Dearnaley)
Clinical Academic Radiotherapy (Huddart)
Oncogenetics
Stereotactic and Precision Body Radiotherapy
Language
eng
Date accepted
2019-09-05
License start date
2019-12
Citation
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019, 141 pp. 174 - 180

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.